Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for purifying protected 2'-deoxycytidines

A technology of deoxycytidines and deoxycytidines, which is applied in the field of crystallization of protected 2'-deoxycytidines and the formation of complexes with water, and can solve problems such as unknown crystallization

Inactive Publication Date: 2008-10-08
MITSUI CHEM INC
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although a non-crystallization method using reprecipitation has been disclosed so far, there is no known method for obtaining crystallization by crystallization

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for purifying protected 2'-deoxycytidines
  • Method for purifying protected 2'-deoxycytidines
  • Method for purifying protected 2'-deoxycytidines

Examples

Experimental program
Comparison scheme
Effect test

reference example 1

[0089] N 4 -Production of benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxycytidine

[0090] 119.0g of N 4 -Benzoyl-2'-deoxycytidine was dissolved in 1.5 L of pyridine. After adding 113.5 g of 4,4'-dimethoxytrityl chloride over 2 hours at room temperature, the mixture was stirred at room temperature for 4 hours. After adding 33.8 g of sodium bicarbonate, the mixture was stirred for another 2 hours, and then the reaction solution was concentrated. 1.2 L of ethyl acetate and 300 mL of water were added to the residue, followed by stirring. A small amount of saturated brine was added for liquid separation, and the organic layer was washed with water again, and dried over anhydrous magnesium sulfate. After filtering and distilling off the solvent, it was purified by silica gel column chromatography using ethyl acetate solvent. While vigorously stirring, the fraction containing the target product was dropped into 2.0 L of diisopropyl ether, followed by stirring at room temperature f...

Embodiment 1

[0092] N 4 Synthesis of crystals of -benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxycytidine complexed with water

[0093] The N synthesized in the reference example 1 4 -The free form of benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxycytidine (2.0g), dissolved in 1,2-dichloroethane ( 5 mmL), water (0.1 g) was added, and crystallization was carried out at -24°C for 1 day. After the obtained crystals were collected by filtration, they were dried under reduced pressure at 50°C to obtain N 4 Crystals of -benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxycytidine complexed with water (0.8 g). By Karl Fischer analysis, the moisture value was 2.7%. In addition, the crystals have clear crystallinity peaks in XRD measurement, especially rapid absorption at 5.6°, 7° and 10.3°. In addition, as measured by DSC, there was an endothermic peak accompanying crystal melting at 109°C.

[0094] The N contained in this complex 4 -Benzoyl-2'-deoxycytidine, N 4 -Benzoyl-3'-O-(4,4'-dimethoxytrityl)-2'-...

Embodiment 2

[0096] N 4 Synthesis of crystals of -benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxycytidine complexed with water

[0097] The N synthesized in the reference example 1 4 The free form (2.0 g) of -benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxycytidine was dissolved in butyl acetate (5 mmL), and the alkane (0.5ml), add water (0.1g) and the N obtained in Example 14 Crystallization of -benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxycytidine complexed with water (10 mg), crystallized under ice-cooling day. After the obtained crystals were collected by filtration, they were dried under reduced pressure at 50°C to obtain N 4 Crystals of -benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxycytidine complexed with water (1.3 g). Moisture value by Karl Fischer analysis was 2.2%. In addition, the crystals have clear crystallinity peaks in XRD measurement, especially rapid absorption at 5.6°, 7°, and 10.3°. In addition, as measured by DSC, there was an endothermic peak accompanying crystal melting ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
wavelengthaaaaaaaaaa
Login to View More

Abstract

A protected 2'-deoxycytidine is purified by precipitating the protected 2'-deoxycytidine represented by general formula (3) in the form of a hydrated crystal from a solution containing the protected 2'-deoxycytidine and water, and by recovering the protected 2'-deoxycytidine: <CHEM> wherein R1 represents a 4-methoxytrityl, 4, 4'-dimethoxytrityl, or triphenylmethyl group; and B1 represents a cytosine group having a protected amino group. The compound represented by general formula (3) may be, in particular, a protected 2'-deoxycytidine represented by formula (4): <CHEM> The 2'-deoxycytidine is used as a raw material for antisense DNA.

Description

technical field [0001] The present invention relates to the crystallization of protected 2'-deoxycytidines and their complexes with water. More specifically, the present invention relates to a method for producing and purifying 5'-protected 2'-deoxycytidines. [0002] 5'-protected 2'-deoxycytidines are compounds that are being developed in recent years and are useful as raw materials for antisense DNA and the like. Background technique [0003] In recent years, with the development of genome-based drugs, antisense DNA medicines have been rapidly developed. Accordingly, the demand for DNA oligomers constituting raw materials and protected deoxynucleosides constituting oligomer raw materials is increasing. On the other hand, in pharmaceutical applications, it is necessary to use extremely high-purity intermediate products in order to suppress by-products generated from impurities contained therein as much as possible. [0004] Hitherto, 5'-protected deoxynucleosides have be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07H19/06C07H1/06C07H19/073B01D9/02
CPCC07H19/06C07H1/06C07D405/04
Inventor 石桥大树长原清辉福入靖松叶泰子
Owner MITSUI CHEM INC